Value of tumor diameter to preoperative carcinoembryonic antigen ratio in evaluating prognosis of non-metastatic colorectal cancer patients

Q4 Medicine

肿瘤研究与临床 Pub Date : 2020-03-28 DOI:10.3760/CMA.J.CN115355-20190613-00250

R. Xu, Tao Yang, T. Xue, Tong-xin Yang

{"title":"Value of tumor diameter to preoperative carcinoembryonic antigen ratio in evaluating prognosis of non-metastatic colorectal cancer patients","authors":"R. Xu, Tao Yang, T. Xue, Tong-xin Yang","doi":"10.3760/CMA.J.CN115355-20190613-00250","DOIUrl":null,"url":null,"abstract":"Objective \nTo explore the value of tumor diameter to preoperative carcinoembryonic antigen (CEA) ratio (TCR) in predicting prognosis of patients with non-metastatic colorectal cancer. \n \n \nMethods \nThe clinical data of 144 patients with colorectal cancer in Hainan Hospital of PLA General Hospital between July 2012 and December 2017 were retrospectively analyzed. Patients were divided into the low TCR group and the high TCR group according to the optimal value of TCR in predicting the disease-free survival (DFS) determined by the receiver operating characteristic curve (ROC). The clinicopathological features of both groups were analyzed, and the influencing factors of DFS were also analyzed by using Cox proportional hazard model. \n \n \nResults \nROC analysis showed that TCR had a certain value in predicting DFS, and area under the curve (AUC) was 0.614 (95% CI 0.507-0.722); when the value of TCR was set at 0.690, the sensitivity and specificity of predicting the 3-year DFS rate was 46.3% and 70.9%, respectively. According to 0.690 of TCR, there were 50 cases in the low TCR ( 0.05). Univariate analysis showed that TCR, preoperative CEA level and TNM stage played a role in predicting DFS of patients (all P < 0.05), while Cox multivariate analysis indicated that TCR < 0.690 (HR = 2.369, 95% CI 1.279-4.388, P = 0.006) and Ⅲ stage in TNM stage (HR = 2.214, 95% CI 1.346-3.640, P = 0.002) were the independent risk factors of influencing DFS (all P < 0.01). The 3-year DFS rate of patients in the low TCR group was lower than that of those in the high TCR group (62.0% vs. 83.0%, P = 0.007). \n \n \nConclusion \nTCR could have a certain value in judging the prognosis of non-metastatic colorectal cancer patients, and low TCR patients have a poorer prognosis. \n \n \nKey words: \nColorectal neoplasms; Tumor diameter; Carcinoembryonic antigen; Disease-free survival; Prognosis","PeriodicalId":9505,"journal":{"name":"肿瘤研究与临床","volume":"32 1","pages":"149-153"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"肿瘤研究与临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.CN115355-20190613-00250","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To explore the value of tumor diameter to preoperative carcinoembryonic antigen (CEA) ratio (TCR) in predicting prognosis of patients with non-metastatic colorectal cancer. Methods The clinical data of 144 patients with colorectal cancer in Hainan Hospital of PLA General Hospital between July 2012 and December 2017 were retrospectively analyzed. Patients were divided into the low TCR group and the high TCR group according to the optimal value of TCR in predicting the disease-free survival (DFS) determined by the receiver operating characteristic curve (ROC). The clinicopathological features of both groups were analyzed, and the influencing factors of DFS were also analyzed by using Cox proportional hazard model. Results ROC analysis showed that TCR had a certain value in predicting DFS, and area under the curve (AUC) was 0.614 (95% CI 0.507-0.722); when the value of TCR was set at 0.690, the sensitivity and specificity of predicting the 3-year DFS rate was 46.3% and 70.9%, respectively. According to 0.690 of TCR, there were 50 cases in the low TCR ( 0.05). Univariate analysis showed that TCR, preoperative CEA level and TNM stage played a role in predicting DFS of patients (all P < 0.05), while Cox multivariate analysis indicated that TCR < 0.690 (HR = 2.369, 95% CI 1.279-4.388, P = 0.006) and Ⅲ stage in TNM stage (HR = 2.214, 95% CI 1.346-3.640, P = 0.002) were the independent risk factors of influencing DFS (all P < 0.01). The 3-year DFS rate of patients in the low TCR group was lower than that of those in the high TCR group (62.0% vs. 83.0%, P = 0.007). Conclusion TCR could have a certain value in judging the prognosis of non-metastatic colorectal cancer patients, and low TCR patients have a poorer prognosis. Key words: Colorectal neoplasms; Tumor diameter; Carcinoembryonic antigen; Disease-free survival; Prognosis

查看原文本刊更多论文

肿瘤直径与术前癌胚抗原比值在评价癌症患者预后中的价值

目的探讨肿瘤直径与术前癌胚抗原（CEA）比值（TCR）对癌症患者预后的预测价值。方法回顾性分析2012年7月至2017年12月解放军总医院海南医院收治的144例癌症大肠癌患者的临床资料。根据受试者操作特征曲线（ROC）确定的TCR预测无病生存期（DFS）的最佳值，将患者分为低TCR组和高TCR组。分析两组患者的临床病理特征，并采用Cox比例风险模型分析DFS的影响因素。结果ROC分析表明，TCR对DFS有一定的预测价值，曲线下面积（AUC）为0.614（95%CI 0.507-0.722）；当TCR值设定为0.690时，预测3年DFS发生率的敏感性和特异性分别为46.3%和70.9%。TCR为0.690，TCR低者50例（0.05）。单因素分析表明，TCR、术前CEA水平和TNM分期对预测患者DFS有一定作用（均P<0.05），Cox多因素分析表明，TCR<0.690（HR=2.369，95%CI 1.279-4.388，P=0.006）和TNMⅢ期（HR=2.214，95%CI 1.346-3.640，P=0.002）是影响DFS的独立危险因素（均P<0.01），低TCR组患者的3年DFS发生率低于高TCR组（62.0%vs.83.0%，P=0.007）对判断癌症患者的预后有一定价值，低TCR患者预后较差。关键词：结直肠肿瘤；肿瘤直径；癌胚抗原；无病生存；预后

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

肿瘤研究与临床 Medicine-Oncology

CiteScore

0.10

自引率

0.00%

发文量

7737

期刊介绍： "Cancer Research and Clinic" is a series of magazines of the Chinese Medical Association under the supervision of the National Health Commission and sponsored by the Chinese Medical Association. It mainly reflects scientific research results and academic trends in the field of malignant tumors. The main columns include monographs, guidelines and consensus, standards and norms, treatises, short treatises, survey reports, reviews, clinical pathology (case) discussions, case reports, etc. The readers are middle- and senior-level medical staff engaged in basic research and clinical work on malignant tumors.